Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain MDXG message board posts where the ticker symbol MDXG has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest MDXG SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001376339-17-000151 (34 Act)  Size: 67 KB
2017-12-13 001-35887
171253065
8-K  Documents Current report, items 2.02, 7.01, and 9.01
Acc-no: 0001376339-17-000149 (34 Act)  Size: 42 KB
2017-11-30 001-35887
171230186
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001376339-17-000146 Size: 5 KB
2017-11-02
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001376339-17-000144 Size: 5 KB
2017-11-02
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001376339-17-000142 Size: 4 KB
2017-11-02
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001376339-17-000140 Size: 5 KB
2017-11-02
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001376339-17-000138 (34 Act)  Size: 5 MB
2017-10-31 001-35887
171166553
8-K  Documents Current report, items 2.02, 5.02, and 9.01
Acc-no: 0001376339-17-000134 (34 Act)  Size: 425 KB
2017-10-26 001-35887
171156445
8-K  Documents Current report, items 2.02, 7.01, and 9.01
Acc-no: 0001376339-17-000129 (34 Act)  Size: 64 KB
2017-10-11 001-35887
171133177
8-K  Documents Current report, items 2.01, 8.01, and 9.01
Acc-no: 0001376339-17-000127 (34 Act)  Size: 281 KB
2017-10-05 001-35887
171125078
More MDXG SEC Filings


Related news from
Sat, 16 Dec 2017
19:35:08 +0000
Does MiMedx Group Inc’s (NASDAQ:MDXG) Past Performance Indicate A Stronger Future?
Examining MiMedx Group Inc’s (NASDAQ:MDXG) past track record of performance is a useful exercise for investors. It allows us to reflect on whether the company has met or exceed expectations,Read More...
Thu, 14 Dec 2017
23:25:00 +0000
MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Sellers
MARIETTA, Ga. , Dec. 14, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental ...
Thu, 14 Dec 2017
19:38:43 +0000
MiMedx Group, Inc. – Value Analysis (NASDAQ:MDXG) : December 14, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives MiMedx Group, Inc. a score of 78. Our analysis is based on comparing MiMedx Group, Inc. with the following peers – Teleflex Incorporated, Medtronic plc, Hill-Rom Holdings, Inc., Sonoma Pharmaceuticals, Inc., CryoLife, Inc., NuVasive, Inc., STERIS Plc, Alphatec Holdings, Inc. and C. R. Bard, Inc. (TFX-US, MDT-US, ... Read more <b>(Read more...)</b>
Thu, 14 Dec 2017
18:49:50 +0000
ETFs with exposure to MiMedx Group, Inc. : December 14, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to MiMedx Group, Inc. Here are 5 ETFs with the largest exposure to MDXG-US. Comparing the performance and risk of MiMedx Group, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more <b>(Read more...)</b>
Wed, 13 Dec 2017
12:15:54 +0000
MiMedx Group, Inc. breached its 50 day moving average in a Bullish Manner : MDXG-US : December 13, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for MiMedx Group, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more <b>(Read more...)</b>
Wed, 13 Dec 2017
12:00:00 +0000
MiMedx Forecasts 2018 Revenue To Be In The Range Of $383 Million To $387 Million
MARIETTA, Ga., Dec. 13, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today its guidance for full year 2018. *Adjusted Diluted Net Income per share consists of GAAP net income excluding: (i) one time acquisition related costs, (ii) amortization of inventory fair value step-up, (iii) amortization of intangible assets, (iv) share-based compensation (v) gain on divestiture and (vi) the normalization of tax expense. During 2017, the Company divested its Stability Biologics subsidiary as it was not a strategic fit with MiMedx's new focus as a predominately biopharmaceutical company.
Tue, 12 Dec 2017
19:37:00 +0000
MiMedx Announces Release Of 2018 Guidance And Shareholder Conference Call
MARIETTA, Ga. , Dec. 12, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental ...
Wed, 06 Dec 2017
16:01:00 +0000
Two Independent Poster Abstracts Highlighting The Clinical Efficacy of MiMedx Allografts are Recognized at The 2017 Desert Foot Conference
MARIETTA, Ga. , Dec. 6, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental ...
Thu, 30 Nov 2017
19:00:00 +0000
MiMedx Issues Shareholder Letter Detailing The Illegal Short Selling The Company Is Experiencing
MARIETTA, Ga. , Nov. 30, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental ...
Thu, 30 Nov 2017
13:45:00 +0000
MiMedx Announces Expectation To Exceed Top End of Fourth Quarter Revenue Guidance Of $88 Million
MARIETTA, Ga., Nov. 30, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today its preliminary expectation for fourth quarter of 2017 revenue to exceed the $88 million high end of its fourth quarter revenue guidance range. Parker H. "Pete" Petit, Chairman and CEO, commented, "October and November have been very strong revenue months for the Company, and we expect our revenue performance in December to be equally strong.  With two-thirds of the fourth quarter completed, and as we enter December, our current revenue pace gives us confidence that we are in a position to announce that we expect to exceed $88 million in revenue for the fourth quarter of 2017 and surpass our previously published guidance for the fourth quarter and full year 2017.
Fri, 24 Nov 2017
15:46:07 +0000
ETFs with exposure to MiMedx Group, Inc. : November 24, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to MiMedx Group, Inc. Here are 5 ETFs with the largest exposure to MDXG-US. Comparing the performance and risk of MiMedx Group, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more <b>(Read more...)</b>
Tue, 21 Nov 2017
16:29:00 +0000
MiMedx to Present at the 29th Annual Piper Jaffray Healthcare Conference
MARIETTA, Ga. , Nov. 21, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental ...
Tue, 21 Nov 2017
14:15:00 +0000
MiMedx Provides Update On Its Reimbursement Coverage
MARIETTA, Ga., Nov. 21, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, provided a reimbursement update today. Parker H. "Pete" Petit, Chairman and Chief Executive Officer, said "With the publication of the Venous Leg Ulcer (VLU) study earlier this quarter, one of the nation's largest not-for-profit health plans serving more than 3 million people recently decided to add EpiFix® coverage for Diabetic Foot Ulcers (DFUs), VLUs and burns. The Company also provided a reimbursement update in light of the recently issued Food and Drug Administration (FDA) Final and Draft Guidance documents related to human tissue titled, "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use" (the "HCT/P Guidance").
Fri, 17 Nov 2017
13:06:00 +0000
MiMedx Market Leadership Well Positioned In Light Of FDA New Guidance Document
MARIETTA, Ga., Nov. 17, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that the Food and Drug Administration (FDA) issued numerous Final and Draft Guidance documents.  Among them was the final Guidance document related to human tissue titled, "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use" (the "HCT/P Guidance").  Additionally, "Evaluation of Devices Used with Regenerative Medicine Advanced Therapies," Draft Guidance for Industry was published (the "RMAT Guidance"). In the final HCT/P Guidance document, FDA updated and clarified its previous draft Guidance documents regarding HCT/Ps.
Thu, 09 Nov 2017
12:50:00 +0000
Detailed Research: Economic Perspectives on MiMedx Group, Zoetis, Six Flags Entertainment, Continental Resources, Boardwalk Pipeline Partners, LP, and Western Union – What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 09, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MiMedx ...
Wed, 08 Nov 2017
19:38:00 +0000
MiMedx To Webcast Its Investor's Day Conference on November 30, 2017
MARIETTA, Ga., Nov. 8, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it will be hosting and webcasting its Investor's Day Conference on Thursday, November 30, 2017.
Wed, 08 Nov 2017
14:00:00 +0000
MiMedx to Present at Jefferies 2017 London Healthcare Conference
MARIETTA, Ga. , Nov. 8, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "Since being one of the beginning members, it has been a great experience. This select group of sophisticated investors has exceptional knowledge to share. The members come from all walks of life and have varied experiences. Many are experts in finance and commodity related issues. Many are good money managers. This is a value oriented group where good yields on a variety of stocks are the main focus." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards